Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Abstract The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests that the rapidly evolving coronavirus subvariants risk rendering vaccines and antibodies ineffective due to their potential to evad...

Full description

Bibliographic Details
Main Authors: Yiying Xue, Husheng Mei, Yisa Chen, James D. Griffin, Qingsong Liu, Ellen Weisberg, Jing Yang
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:MedComm
Subjects:
combination therapy
drug resistance
pathogenic targets
repurposing therapies
SARS‐CoV‐2
Online Access:https://doi.org/10.1002/mco2.254

Internet

https://doi.org/10.1002/mco2.254

Similar Items